• argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis

    Thursday September 21st 2023

  • SwiftPharma and the Population Council Pursue Agreement to Manufacture Griffithsin Needed for the Development of a Fast-Dissolving Insert for Protection Against HIV

    Friday September 8th 2023

  • SwiftPharma and AntoXa Corporation sign exclusive collaboration agreement to support the development and commercialization of a plant-made antibody against ricin exposure

    Friday September 1st 2023

  • AI assists in arthritis diagnosis based on MRI images

    Monday August 28th 2023

  • argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy

    Monday July 17th 2023

  • VUB neurologist argues for affordability of new Alzheimer’s drug

    Friday July 14th 2023

  • Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure

    Monday July 10th 2023

  • argenx and Zai Lab announce approval of VYVGART® (efgartigimod alfa injection) for generalized myasthenia gravis in China

    Friday June 30th 2023

  • Your news here?

  • argenx announces U.S. Food and Drug Administration approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in generalized myasthenia gravis

    Wednesday June 21st 2023

  • Oxurion finalizes enrollment in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema

    Monday June 12th 2023

  • Scientists shed light on a sleep peptide involved in Alzheimer’s

    Wednesday May 17th 2023

Strategic Partners